Dr. Jeffrey Tobias, Chief Medical Officer, noted, "NeurogesX is proud to be able to provide this new treatment option for non-diabetic patients with peripherial neuropathic pain. These patients will now have access to a non-systemic treatment delivered directly to the site of pain that can produce up to three months of pain relief following a single 30- or 60-minute application."
In October 2008, the Company submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) requesting marketing approval of Qutenza for the management of pain associated with postherpetic neuralgia (PHN). In December 2008, the NDA was accepted by the FDA for review, resulting in a Prescription Drug User Fee Act (PDUFA) date of August 16, 2009.
About Neuropathic Pain
Neuropathic pain is a type of chronic pain that results from injury to, or dysfunction of, nerves in the central or peripheral nervous systems. Peripheral neuropathic pain is an inappropriate sensation of pain that results when injured or dysfunctional nerve endings send aberrant pain signals to the brain, in the absence of harmful stimuli. It can result from viruses, in cases of postherpetic neuralgia (PHN) and painful HIV-distal sensory polyneuropathy (HIV-DSP), or diseases, such as diabetes.
An estimated 8% of the world's population and an estimated 3.0 million people in Europe suffer from neuropathic pain. The market for neuropathic pain is quic
|SOURCE NeurogesX, Inc.|
Copyright©2009 PR Newswire.
All rights reserved